share_log

BRIEF-Metacrine Reports Interim Results For Met642 Phase 2A Trial In Patients With NASH

Reuters ·  Oct 22, 2021 05:46

Oct 21 (Reuters) - Metacrine, Inc. MTCR.O :

* METACRINE REPORTS INTERIM RESULTS FOR MET642 PHASE 2A TRIAL IN PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION OF ITS CLINICAL DEVELOPMENT PROGRAMS

* METACRINE - PRIORITIZING CLINICAL DEVELOPMENT EFFORT AND RESOURCES TO ADVANCE MET642 INTO A PHASE 2 TRIAL IN IBD IN FIRST HALF OF 2022

* METACRINE, INC. - EXPECTS INDEPENDENT REVIEW OF MET642 TO BE COMPLETED BEFORE END OF 2021

* METACRINE, INC. - CONDUCTING AN INDEPENDENT REVIEW OF PRELIMINARY FINDINGS FROM A RECENTLY COMPLETED NINE-MONTH ANIMAL TOXICOLOGY STUDY FOR MET642

* METACRINE, INC. - TO HALT FUTURE DEVELOPMENT OF FXR PROGRAM IN NASH

* METACRINE, INC. - DECISION WAS INFLUENCED IN PART BY A POTENTIAL DELAY IN CONFIRMING APPROPRIATE SAFETY MARGINS IN LONG-TERM TOXICOLOGY WORK

* METACRINE, INC. - MET642 WAS GENERALLY WELL-TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS

Source text for Eikon: Further company coverage:

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment